This episode covers the FDA’s January twenty twenty six final guidance broadening general wellness exemptions and clinical decision support enforcement discretion, the August twenty twenty five Predetermined Change Control Plan framework for AI device lifecycle management, the FDA EMA joint Good AI Practice principles for trial systems, updated February twenty twenty six cybersecurity guidance under Section five twenty four B, confirmation of single trial defaults for drug approval, and the draft pathway for individualized gene editing therapies using first in human studies as pivotal trials. Listeners heard how documentation and transparency requirements now define regulatory classification for AI tools, how PCCP mechanisms allow iterative algorithm updates within existing premarket pathways, and how evidentiary standards are shifting from trial quantity to trial quality across both conventional and precision modalities.